

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 5, 2009 (use as many sheets as necessary)			Complete if Known		
Sheet	1	of	3	Application Number	10/522,664
				Filing Date	7/31/2003
				First Named Inventor	Heinz-Josef Lenz
				Art Unit	1634
				Examiner Name	Carla J. Myers
				Attorney Docket Number	064189-0604

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Application Document Serial Number-Kind Code ² (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					T ⁶

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/CM/	D28	CHANG et al. (2008) "ERCC1 codon 118 C-T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma" Cancer Sci. 100(2):278-283			
/CM/	D29	HUANG et al. (2008) "ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer" World J. Gastroenterol. 14(41):6401-6407			
/CM/	D30	ISLA et al. (2004) "Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer" Annals of Oncology 15:1194-1203			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the month is omitted. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: March 5, 2009

(use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	10/522,664
Filing Date	7/31/2003
First Named Inventor	Heinz-Josef Lenz
Art Unit	1634
Examiner Name	Carla J. Myers
Attorney Docket Number	064189-0604

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. [†]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/CM/	D31	KAMIKOZURU et al. (2008) "ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy" International Journal of Oncology 32 :1091-1096	
	D32	KANG et al. (2008) "Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer" Experimental and Molecular Medicine 38 (3):320-324	
	D33	KEAM et al. (2008) "Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker" BMC Cancer 8 :148, 10 pgs	
	D34	KRIVAK et al. (2008) "Relationship Between ERCC1 Polymorphisms, Disease Progression, and Survival in Gynecologic Oncology Group Phase III Trial of Intrapitoneal Versus Intravenous Cisplatin and Paclitaxel for Stage III Epithelial Ovarian Cancer" J. Clin. Oncol. 26 (21):3598-3606	
	D35	LIU et al. (2005) "Impact of Gene Polymorphisms on Clinical Outcome for Stage IV Melanoma Patients Treated with Biochemotherapy: An Exploratory Study" Clin. Cancer Res. 11 :1237-1246	
	D36	MARTINEZ-BALIBREA et al. (2008) "Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer" European J. of Cancer 44 :1229-1237	
	D37	PARE et al. (2008) "Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy" British J. Cancer 99 :1050-1055	
	D38	PARK et al. (2006) "Effect of ERCC1 Polymorphisms and Modification by Smoking on the Survival of Non-Small Cell Lung Cancer Patients" Medical Oncology 23 (4):489-498	
	D39	RUZZO et al. (2007) "Pharmacogenetic Profiling in Patients with Advanced Colorectal Cancer treated with First-Line FOLFOX-4 Chemotherapy" J. Clin. Oncol. 25 (10):1247-1254	
	D40	RYU et al. (2004) "Association between polymorphism of ERCC1 and XPD and Survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy" Lung Cancer 44 :311-316	
	D41	SMITH et al. (2007) "ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit from Paclitaxel Treatment in Addition to Platinum-Based Therapy" J. Clin. Oncol. 25 (33):5172-5179	
V	D42	STEFFENSEN et al. (2008) "Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer" Int. J. Gynecol. Cancer 18 :702-710	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the indication of the year of the document. 5 Indicate the filing or issue date by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if Examiner language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to be (and is) used by the USPTO to process an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/522,664
Date Submitted: March 5, 2009		Filing Date	7/31/2003
(use as many sheets as necessary)		First Named Inventor	Heinz-Josef Lenz
Sheet	3	Art Unit	1634
		Examiner Name	Carla J. Myers
		Attorney Docket Number	064189-0604

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. [†]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T [‡]
/CM/	D43	STOEHLMACHER et al. (2004) "A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer" British J. Cancer 91:344-354		
/CM/	D44	SUK et al. (2005) "Polymorphisms in ERCC1 and Grade 2 or 4 Toxicity in Non-Small Cell Lung Cancer Patients" Clin. Cancer Res. 11:1534-1538		
/CM/	D45	TIBALDI et al. (2008) "Correlation of CDA, ERCC1, and XPD polymorphisms with Response and Survival in Gemcitabine/Cisplatin - Treated Advanced Non-Small Cell Lung Cancer Patients" Clin. Cancer Res. 14(6):1797-1803		
/CM/	D46	ZHOU et al. (2004) "Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy" Clin. Cancer Res. 10:4939-4943		

Examiner Signature	/Carla Myers/	Date Considered	04/01/2009
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the Office and the two-letter code of the Japanese Patent Office should precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 (see below). 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is mandatory to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.